FDA gives nod to AtriCure's LAA exclusion system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has given the green light to AtriCure’s AtriClip Gillinov-Cosgrove left atrial appendage (LAA) exclusion system for use in conjunction with other open-heart cardiac procedures.

According to the West Chester, Ohio-based company, the AtriClip system is equipped with a clip device that excludes the LAA during an intervention to prevent the formation of blood pools in the LAA that have the potential to clot, particularly during atrial fibrillation.

The company said that marketing of the product will begin next month and the full release will begin in the third quarter of this year.